Cargando…

Effect of Opicapone Tablets on Levodopa and 3‐O‐Methyldopa Pharmacokinetics in Healthy Japanese Subjects: Phase 1 Study

This study evaluated the effect of a small‐tablet formulation of opicapone for use in clinical trials in Japan on the pharmacokinetics of levodopa (l‐dopa) and 3‐O‐methyldopa (3‐OMD). In an open‐label, 3‐period, single‐sequence crossover phase 1 study in 80 healthy Japanese males (aged 20‐45 years;...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nomoto, Masahiro, Takeda, Atsushi, Iwai, Katsuaki, Nishimura, Akihisa, Hattori, Nobutaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891606/ https://www.ncbi.nlm.nih.gov/pubmed/32416054 http://dx.doi.org/10.1002/cpdd.799

Ejemplares similares

Pharmacokinetic Comparison of Capsule and Tablet Formulations of Opicapone in Healthy Japanese Subjects: Phase 1 Study
por: Nomoto, Masahiro, et al.
Publicado: (2020)

Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients with Motor Fluctuations
por: Takeda, Atsushi, et al.
Publicado: (2020)

Long-term safety and efficacy of opicapone in Japanese Parkinson’s patients with motor fluctuations
por: Takeda, Atsushi, et al.
Publicado: (2021)

Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson's Disease
por: Ferreira, Joaquim J., et al.
Publicado: (2022)

Pharmacokinetics of Levodopa and 3-O-Methyldopa in Parkinsonian Patients Treated with Levodopa and Ropinirole and in Patients with Motor Complications
por: Adamiak-Giera, Urszula, et al.
Publicado: (2021)

Opicapone Pharmacokinetics and Effects on Catechol-O-Methyltransferase Activity and Levodopa Pharmacokinetics in Patients With Parkinson Disease Receiving Carbidopa/Levodopa
por: LeWitt, Peter, et al.
Publicado: (2023)

Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson’s disease
por: Hattori, Nobutaka, et al.
Publicado: (2019)

Evaluating Opicapone as Add-on Treatment to Levodopa/DDCI in Patients with Parkinson’s Disease
por: Jost, Wolfgang H
Publicado: (2022)

Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinetics and Pilot Efficacy and Safety
por: Othman, Ahmed A., et al.
Publicado: (2015)

Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson’s Disease Patients
por: Müller, Thomas, et al.
Publicado: (2022)

Spotlight on opicapone as an adjunct to levodopa in Parkinson’s disease: design, development and potential place in therapy
por: Annus, Ádám, et al.
Publicado: (2017)

Pharmacokinetics and safety/efficacy of levodopa pro-drug ONO-2160/carbidopa for Parkinson's disease
por: Nomoto, Masahiro, et al.
Publicado: (2018)

Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets
por: Othman, Ahmed A, et al.
Publicado: (2014)

Long-term effects of safinamide adjunct therapy on levodopa-induced dyskinesia in Parkinson’s disease: post-hoc analysis of a Japanese phase III study
por: Hattori, Nobutaka, et al.
Publicado: (2022)

Correction: Long-term effects of safinamide adjunct therapy on levodopa-induced dyskinesia in Parkinson’s disease: post-hoc analysis of a Japanese phase III study
por: Hattori, Nobutaka, et al.
Publicado: (2022)

Degradation of Methyldopa by Banana
por: Uesawa, Yoshihiro, et al.
Publicado: (2010)

The Use of Methyldopa in the Elderly
por: Ramsay, L.E.
Publicado: (1981)

Pharmacokinetic Profiles of Ticagrelor Orodispersible Tablets in Healthy Western and Japanese Subjects
por: Teng, Renli, et al.
Publicado: (2017)

Pharmacokinetics, Pharmacodynamics, and Tolerability of Opicapone in Healthy Chinese and Caucasian Subjects: An Open-Label, Single-Center, Phase 1 Study
por: Cong, Duanduan, et al.
Publicado: (2022)

Opicapone for Parkinson’s disease
Publicado: (2023)

Methyldopa-induced connective tissue disorder.
por: Power, M. J., et al.
Publicado: (1986)

Efficacy and Safety of Opicapone for Motor Fluctuations as an Adjuvant to Levodopa Therapy in Patients with Parkinson’s Disease: A Systematic Review and Meta-Analysis
por: Kwak, Nayoung, et al.
Publicado: (2022)

Absorption, metabolism and excretion of opicapone in human healthy volunteers
por: Loureiro, Ana I., et al.
Publicado: (2022)

The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson’s disease: opicapone versus entacapone
por: Leta, Valentina, et al.
Publicado: (2023)

Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinson’s disease patients
por: Senek, Marina, et al.
Publicado: (2018)

Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson’s disease
por: Hattori, Nobutaka, et al.
Publicado: (2019)

Pharmacokinetics and Safety of Defibrotide in Healthy Japanese Subjects
por: Umemura, Kazuo, et al.
Publicado: (2016)

Opicapone: A third generation COMT inhibitor
por: Greenwood, Jessica, et al.
Publicado: (2020)

Continuous 24-h Levodopa-Carbidopa Intestinal Gel Infusion After a Levodopa Holiday Suppressed Refractory Dyskinesia Despite Increasing Levodopa Dose
por: Nishikawa, Noriko, et al.
Publicado: (2022)

Collective Expert Perspectives on the Use of Safinamide as Adjunctive Therapy for Parkinson's Disease: Online-Based Delphi Survey
por: Takeda, Atsushi, et al.
Publicado: (2022)

Pharmacokinetics of the most commonly used antihypertensive drugs throughout pregnancy methyldopa, labetalol, and nifedipine: a systematic review
por: van de Vusse, Dylan, et al.
Publicado: (2022)

The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II
por: Rocha, José-Francisco, et al.
Publicado: (2021)

The safety/tolerability of opicapone when used early in Parkinson's disease patients with levodopa-induced motor fluctuations: A post-hoc analysis of BIPARK-I and II
por: Rocha, José-Francisco, et al.
Publicado: (2022)

Opicapone as an Add-on to Levodopa in Patients with Parkinson’s Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial
por: Ferreira, Joaquim J., et al.
Publicado: (2022)

Bioequivalence of perampanel fine granules and tablets in healthy Japanese subjects
por: Shiba, Sari, et al.
Publicado: (2020)

Metabolism and disposition of opicapone in the rat and metabolic enzymes phenotyping
por: Loureiro, Ana I., et al.
Publicado: (2021)

The Bioequivalence and Effect of Food on the Pharmacokinetics of a Fixed‐Dose Combination Tablet Containing Rosuvastatin and Ezetimibe in Healthy Japanese Subjects
por: Nishida, Chisato, et al.
Publicado: (2019)

Gender Differences in Levodopa Pharmacokinetics in Levodopa-Naïve Patients With Parkinson’s Disease
por: Conti, Valeria, et al.
Publicado: (2022)

Comparison of pharmacokinetic characteristics of sildenafil citrate chewable tablets and film-coated tablets in healthy male subjects
por: Yoo, Hyounggyoon, et al.
Publicado: (2017)

Levodopa Prescription Patterns in Patients with Advanced Parkinson's Disease: A Japanese Database Analysis
por: Takeda, Atsushi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_m4m4lloenfi94p4iirdiv4vofr